Onesource Specialty Pharma Limited is a biotechnology company specializing in the research, development, manufacturing, and commercialization of biological drug products, primarily in injectable formats. Originally incorporated as Inbiopro Solutions Private Limited in June 2007, the company underwent multiple name changes and structural transformations, culminating in its current name in February 2024. The company transitioned to a public entity in July 2021 and executed a significant merger through a Scheme of Arrangement in November 2024, which integrated operations with Strides Pharma Science Limited and Steriscience Specialties Private Limited.
The Scheme of Arrangement enabled Onesource Specialty Pharma Limited to acquire and consolidate the biologics and DDC, soft gelatin capsule, and injectables businesses of Strides Pharma and Steriscience, positioning the company as a comprehensive player in the biologics sector. Following the merger, the company issued 1.14 billion equity shares and significantly expanded its operational and service capabilities.
Today, Onesource Specialty Pharma Limited operates 5 globally compliant manufacturing facilities that service leading generic pharmaceutical companies, biopharmaceutical innovators, and dedicated R&D houses worldwide. In addition to its biological products, the company provides Contract Development and Manufacturing Operations (CDMO) services, supporting clients across all stages of preclinical development, clinical trials, and commercial production. This diversified portfolio allows the company to cater to both established players and emerging biotech firms.
By leveraging its global manufacturing footprint and end-to-end CDMO services, Onesource Specialty Pharma Limited positions itself as a key player in the biotechnology sector, offering high-quality injectable biologics and tailored development solutions to meet the dynamic needs of the pharmaceutical industry.
